











**a****b****c****d**


**Supplementary Figure 1.** Global properties of single-cell RNA-Seq libraries. **a)** Number of cells captured and passing quality control filters (methods) per Fluidigm C1 chip. **b)** Mapped fragments per cell. **c)** Fraction of per-cell cumulative expression, by biotype. **d)** Mean standardized distribution of log-transformed FPKMs across cells (black) compared to the standard normal distribution (red).




**Supplementary Figure 2.** Concordance of FPKMs between bulk and single-cell RNA-Seq libraries. **a)** Gene expression values from two replicate off-chip control libraries prepared from ~250 cells collected in GM (time zero). **b)** The cross-cell average expression level from single cell-libraries collected at time zero compared against the off-chip control library. **c)** The off-chip control library compared against the bulk RNA-Seq library average. **d)** Log-transformed fold changes in gene expression between zero and 72 hours obtained from bulk RNA-Seq compared against those from the single-cell averages at the corresponding time points. Facets correspond to the four quartiles of gene expression (in FPKM determined by bulk RNA-Seq). **e)** The cross-cell average expression level from single cell-libraries collected after 48 hours in DM compared against the off-chip control library prepared from ~250 cells collected at the same time. **f)** On-and off-chip measurements of four genes expressed at high levels in large, multinucleated myotubes.

a


Bulk RNA-Seq FPKM






b



c




**Supplementary Figure 3.** Variability in gene expression across individual cells. **a)** Cumulative fraction of genes detectable in varying fractions of cells, segregated by bulk RNA-seq expression quartile. **b)** Cumulative fraction of cells with varying levels of correlation with bulk RNA-Seq libraries. Comparisons of cells with bulk libraries at the same points are shown as solid lines. Dashed lines indicate comparisons of cells with bulk libraries from different time points. All genes are segregated by expression quartile, as in panel A. **c)** Gene sets from the Biological Process gene ontology that are significantly more detectable (yellow) and less detectable (violet) at or greater than FPKM 1 across cells at each time point. Black boxes indicate statistical significance at an FDR < 5% (Wilcoxon rank-sum test).




$\log_{10}(\text{FPKM})$


- 1
- 0
- 1
- 2







**Supplementary Figure 4.** Cell identity and properties of HSMM culture. **a)** Muscle lineage and mesenchymal marker expression levels in each cell represented in the two-dimensional independent component space. The size of each circle is proportional to the expression level of the indicated mRNA in that cell. The percentage of cells expressing each marker at or above FPKM 1 in each of three populations identified by Monocle: proliferating cells (red), myocytes/myotubes (blue) or mesenchymal fibroblasts (green). Highly proliferating cells are positive for the cyclin CDK1, which is absent in both terminally differentiated fibroblasts or myotubes. The majorities of the proliferating cells are positive for muscle lineage markers MYF5, NCAM1 or MSTN (not shown), and negative for MYOG. In contrast, PDGFRA identifies cells of mesenchymal origin, and presence of both SPHK1 and ACTA2 (not shown) suggests a myofibroblast-like contractile capacity. (Cyclin dependent kinase 1, CDK1; Myogenic factor 5, MYF5; Neural cell adhesion molecule 1, NCAM1; Myogenin, MYOG; Actin, alpha 2, smooth muscle, ACTA2; Sphingosine kinase 1, SPHK1; Platelet derived growth factor receptor alpha, PDGFRA; Myostatin, MSTN). **b)** Cell subpopulation sizes at each time point. **c)** Immunofluorescence analysis of HSMM culture in GM or 72h after switch to DM. Cells of mesenchymal origin report high levels of the surface marker CD13 (green) and mitotic cells are enriched in the nuclear phosphorylated H3-Ser10 (red). Hoechst DNA staining highlights all nuclei (blue). Scale bar corresponds to 100  $\mu$ m. In GM, proliferating cells are phospho-H3+ and either CD13+ and CD13- (see magnification below) indicating that both mesenchymal cells (CD13+) and non-mesenchymal cells (myoblasts, CD13-) are actively proliferating. In DM all phospho-H3+ cells are also CD13+ suggesting that at this stage fibroblasts are the only proliferating cells. **d)** Bar plots showing the proportion of fibroblasts along the differentiation trajectory measured by expression of CD13 by immunofluorescence (left panel) and RNA-seq (right panel). **e)** Bar plots showing the total proliferating cells with respect to proliferating mesenchymal cells measured by immunofluorescence (left panel - phospho-H3 positive cells with respect to double positive CD13/phospho-H3 cells) and RNA-seq (right panel - CDK1+ cells with respect to CDK1+/CD13+ cells).




**Supplementary Figure 5.** Markers of myogenic differentiation in pseudo-time reordered cells. (Cyclin A2, CCNA2; Cyclin B2, CCNB2; Minichromosome maintenance 4, MCM4; Muscle creatine kinase, CKM; Enolase 3, ENO3; Myosin heavy chain 3, MYH3; Myogenin, MYOG; Troponin type 3, TNNT3; Tropomyosin 1, TPM1; Hairy/enhancer-of-split 1, HES1; Myocyte enhancer factor 2 C, MEF2C; Myogenic factor 5, MYF5)




**Supplementary Figure 6.** Conservation of gene expression dynamics for key molecular markers of myogenesis. Each heatmap shows a block of genes previously reported by Blais et al to be targets of Myod, Myog, or a member of the Mef2 family of transcription factors. The change in expression between C2C12 mouse myoblasts and their derived myotubes is shown in the right column for each block. The heatmap shows the human expression level for each gene in each cell, with columns corresponding to cells placed in pseudo-time order. The statistical significance of pseudo-time dependent changes in expression (as reported by a likelihood ratio test, see Methods) are reported as log-transformed p-values in the middle column. Genes are grouped according to their function and discussion in the study by Blais et al.





**Supplementary Figure 7.** Robustness of Monocle as assessed by cross-validation simulation experiments. Randomly sampled subsets of cells were ordered with Monocle as described in the Supplemental Methods. In each panel, the x axis displays the number of cells in the subsets used for cross-validation. Each colored point corresponds to a distinct randomly selected subset, and the colored lines indicate the mean value of the metric on the vertical axis. **a)** Consistency of pseudotime ordering. The vertical axis shows correlation between the pseudotime values of cells ordered as a subset and ordered as part of the full data set. **b)** Consistency of the trend of expression of genes from Supplemental Figure 6. The vertical axis shows the average correlation between the genes under subset orderings and their expression values ordered as part of the full data set. **c)** Precision of dynamically regulated genes under subset ordering (precision = # true positives / (# true positives + # false positives)). **d)** Recall of dynamically regulated genes under subset ordering (recall = # true positives / (# true positives + # false negatives)). True positives and true negatives were defined as genes that marked significantly dynamically regulated or not significantly regulated (respectively) by Monocle on the full data set.





**Supplementary Figure 8.** Gene ontology enrichments for each distinct cluster of (pseudo) temporally regulated genes. Black boxes indicate statistical significance at an FDR < 5% (Wilcoxon rank-sum test).




**Supplementary Figure 9.** Bulk RNA-Seq and single-cell data without reordering compresses the dynamic range of expression. **a)** K-means of bulk RNA-Seq produces two non-redundant trends in gene expression. **b)** DE genes identified by Cuffdiff 2 between any pair of time points using bulk RNA-Seq, compared against DE genes found by Monocle using single cell RNA-Seq. The right venn diagram shows overlap between genes from single-cell RNA-Seq and those with at least a 2-fold change between some pair of time points in bulk RNA-Seq. **c)** Expression levels of selected marker genes measured by bulk RNA-Seq (left), single-cell RNA-Seq ordered by time collected (middle), and pseudo-time reordered single cell RNA-Seq (right). Grey ribbons in the left panel indicate 95% confidence intervals produced by Cuffdiff 2 as part of its model of variability across biological replicates. Boxplots in the middle panel are colored by time point, and these colors are applied to cells in the right panel, indicating the time at which they were collected. Black lines in the left panel indicate a generalized additive model of pseudo-time vs each gene's expression level. **d)** Cumulative distribution of gene expression dynamic range, defined as the maximum FPKM less the minimum FPKM, by three different sources of expression measurement. **e)** Cumulative distributions of normalized root mean squared error (RMSE) of generalized additive models of expression for both unordered and pseudo-time ordered single cell expression profiles

**a****b**


**Supplementary Figure 10.** Enrichments of conserved transcription factor binding motifs in regulatory elements proximal to genes from each of four distinct (pseudo) temporally regulated clusters. **a)** Each column denotes a set of regulatory elements. Columns for regulatory elements are grouped according to the cluster of genes to which they are proximal. Each row indicates a binding site motif for a transcription factor or a family of transcription factors. A yellow cell indicates that the factor's binding site motif is enriched in the corresponding regulatory elements, while a violet one indicates depletion. Black bars indicate significance at an FDR of < 5% (Wilcoxon rank-sum test). **b)** Number of HSMM DNase hypersensitive sites proximal to genes in each of the six clusters, as classified by ENCODE according to function.




**Supplementary Figure 11** Enrichments of conserved transcription factor binding motifs in regulatory elements proximal to genes from each of two temporally regulated clusters, as measured by bulk RNA-Seq. **a)** Each column denotes a set of regulatory elements. Columns for regulatory elements are grouped according to the cluster of genes to which they are proximal. Each row indicates a binding site motif for a transcription factor or a family of transcription factors. A yellow cell indicates that the factor's binding site motif is enriched in the corresponding regulatory elements, while a violet one indicates depletion. Black bars indicate significance at an FDR of  $< 5\%$  (Wilcoxon rank-sum test). **b)** Overlap of transcription factor bidding site motifs associated with regulatory elements in bulk RNA-Seq and single-cell RNA-Seq temporal or pseudotemporal clusters.



**Supplementary Figure 12.** Enrichments of microRNA family target sites in genes belonging to each cluster. Black bars indicate significance at an FDR of < 5% (Wilcoxon rank-sum test)

**a**

**Supplementary Figure 13.** shRNA-mediated knockdown of 11 candidate regulators of myogenesis. **a)** Representative immunofluorescence analysis showing whole-well ( $0.32 \text{ cm}^2$ ) MYH2 staining (red) after 4 days of culture in differentiation medium following shRNA viral infection for the indicated transcripts. Hoechst DNA staining highlights all nuclei (cyan). **b)** qPCR analysis showing residual expression of the indicated mRNA upon RNAi, relative to mock (luciferase) shRNA controls. For each mRNA, four independent shRNA were tested and the interference results of the best two are reported.

**b**

## Supplementary Tables

**Table qPCR primers used to verify knockdown efficiency**

Gene	Target transcript	Forward primer	Reverse primer
<b>AHR</b>	NM_001621.2	ACAACCACATAGTCGTTACCT	AGGACAGTAAAGTTGGTAGGGTG
<b>ARID5B</b>	NM_032199.1	CGATGCTGAAACGCATCCAG	AGGATCTGAGGGTCTCGCT
<b>BACH1</b>	NM_001186.2	GCCTCAGCTCTGGTTGATGATA	TGTCGGGAAGTTCACTGGAAA
<b>CUX1</b>	NM_001913.2	TCTCATGCCAATCACTCC	CTCTATGCCCTGCTCCACG
<b>DDIT3</b>	NM_004083.4	TCAGAGCTGGAACCTGAGGA	GTCGGAGAGGAGAAAGGCAA
<b>HIVEP2</b>	NM_006734.3	TCCTCACGCTTGCAGTCAT	GCTCTGTTGCTTCTGGCTG
<b>MYOG</b>	NM_002479.4	TAAACGCCTTGATGTGCAGC	GCTGGGTGCCATTAAACCC
<b>MZF1</b>	NM_003422.2	CCGTAGAGAAGGGCAGACAC	GCCTCATAGAGGGTACCAAGG
<b>PATZ1</b>	NM_014323.2	TACTTGCAGGGCAGCATAACAT	AGAGGAGAAACCTCGGTTACAG
<b>POU2F1</b>	NM_002697.2	CTGATTGCTCCCTCTCCAGC	CTGGTGCCTTCTCCCTCCT
<b>RREB1</b>	NM_002955.4	ATCTGCCCCATGACTAAGGC	CACCACTCCTGAAACACACA
<b>USF1</b>	NM_007122.3	TTGTGCTCCTCTCGACAAT	CAGGACAAGCCCCAGAGTTT
<b>XBP1</b>	NM_005080.3	AAGCCAAGGGGAATGAAGTGA	AGAGGTGCACGTAGTCTGAG
<b>ZIC1</b>	NM_003412.3	CGAAACACATGAAGGTCCA	CGGGCAAGGCTGCGA

**Table shRNA hairpin sequences used for knockdown**

Gene	Clone ID	shRNA	Vector	Forward Oligo Sequence	Reverse Oligo Sequence
<b>AHR</b>	TRCN0000245286	1	pLKO_TRC005	CCGGATCCACAGTCAGCC ATAATAACTCGAGTTATTAT GGCTGACTGTGGATTTTT TG	AATTCAAAAATCCACA GTCAGCCATAATAACTC GAGTTATTATGGCTGACT GTGGAT
<b>AHR</b>	TRCN0000021258	2	pLKO.1	CCGGCGGCATAGAGACC GACTTAATCTCGAGATTAA GTCGGTCTCTATGCCGTT TTTG	AATTCAAAAACGGCATA GAGACCGACTTAATCTC GAGATTAAGTCGGTCTC TATGCCG
<b>AHR</b>	TRCN0000245283	3	pLKO_TRC005	CCGGGCGGCATAGAGAC CGACTTAACTCGAGTTAA GTCGGTCTCTATGCCGCT TTTG	AATTCAAAAAGCGGCAT AGAGACCGACTTAACCTC GAGTTAAAGTCGGTCTCT ATGCCGC
<b>AHR</b>	TRCN0000245285	4	pLKO_TRC005	CCGGGCAACAAGATGAGT CTATTTACTCGAGTAAATA GACTCATTTGTTGCTTTT TG	AATTCAAAAAGCAACAA GATGAGTCTATTTACTCG AGTAAATAGACTCATCTT GTTGC
<b>ARID5B</b>	TRCN0000365579	1	pLKO_TRC005	CCGGTACCCTTAGCTGC TATAATCTCGAGATTATA GCAGCTAAAGGGTATTTT TG	AATTCAAAAATACCCCTT AGCTGCTATAATCTCGA GATTATAGCAGCTAAAG GGTA
<b>ARID5B</b>	TRCN0000370799	2	pLKO_TRC005	CCGGATAGAGTTAGAAGT CACTTACTCGAGAAACT GACTTCTAACTCTATTTTT TG	AATTCAAAAATAGAGTT AGAAGTCAGTATTCTCG AGAATACTGACTTCTAAC TCTAT
<b>ARID5B</b>	TRCN0000365578	3	pLKO_TRC005	CCGGATAGAACGAATACC CTATTTACTCGAGTAAATA GGGTATTGTTCTATTTTT TG	AATTCAAAAATAGAACG AATACCCATTACTCGA GTAATAGGGTATTGCGTT CTAT
<b>ARID5B</b>	TRCN0000370859	4	pLKO_TRC005	CCGGTGCATGAGTTGC GCCAAATCTCGAGATTG GCGAAACTCATCGCATT TTTG	AATTCAAAAATGCGATG AGTTGCGCCAACTCTC GAGATTGGCGCAAACCT CATCGCA

<b>BACH 1</b>	TRCN0000433926	1	pLKO_TRC005	CCGGGCATATCAGACAGC AATTAACTCGAGTTAAT TGCTGTCTGATATGCTTT TG	AATTCAAAAAGCATATCA GACAGCAATTAACTCG AGTTAAATTGCTGTCTGA TATGC
<b>BACH 1</b>	TRCN0000430446	2	pLKO_TRC005	CCGGGAAATTGGAACGA TGATTATCTCGAGATAATC ATCGTTCCAATTCTTT TG	AATTCAAAAAGAAATTG GAAACGATGATTATCTC GAGATAATCATCGTTCC AATTTC
<b>BACH 1</b>	TRCN0000416033	3	pLKO_TRC005	CCGGAGCGTCTTGAAG CCTAATATCTCGAGATATT AGGCTTCAAGACGCTTT TTTG	AATTCAAAAAGCGTCT TGAAGCCTAATATCTCG AGATATTAGGCTTCAAG ACGCT
<b>CUX1</b>	TRCN0000013749	1	pLKO.1	CCGGGCCGACAACATCAA GCTTTCTCGAGAAAAGA GCTTGATTTGTCGGCTT TTTG	AATTCAAAAAGCCGACA ACATCAAGCTTTCTC GAGAAAGAGCTTGATGT TGTGGC
<b>CUX1</b>	TRCN0000013751	2	pLKO.1	CCGGCGGCTTCTTCTACA CACTTTCTCGAGAACAG TGTGTAGAAGAAGCCGTT TTTG	AATTCAAAAACGGCTTC TTCTACACACTGTTCTC GAGAACAGTGTGTAGAA GAAGCCG
<b>CUX1</b>	TRCN0000428064	3	pLKO_TRC005	CCGGACCAGATTCCAGCTG CGGTTAACCGAGTTAAC CGCAGCTGAATCGGTTT TTTG	AATTCAAAAACCGATTTC CAGCTGCGGTTAACCG AGTTAACCGCAGCTGGA ATCGGT
<b>CUX1</b>	TRCN0000413385	4	pLKO_TRC005	CCGGAGATCCCAGAGCC CATCAAAGCTCGAGCTTT GATGGGCTCTGGGATCTT TTTG	AATTCAAAAAGATCCC AGAGCCCATAAAGCTC GAGCTTGATGGGCTCT GGGATCT
<b>DDIT 3</b>	TRCN0000364393	1	pLKO_TRC005	CCGGTGAACGGCTCAAG CAGGAAATCTCGAGATT CCTGCTTGAGCCGTTCAT TTTG	AATTCAAAAATGAACGG CTCAAGCAGGAAATCTC GAGATTTCTGCTTGAG CCGTTCA
<b>DDIT 3</b>	TRCN0000364328	2	pLKO_TRC005	CCGGCTGCACCAAGCAT GAACAATTCTCGAGAATT GTTCATGTTGGTGCAGT TTTG	AATTCAAAAATGCACC AAGCATGAACAAATTCTC GAGAATTGTTCATGCTT GGTGCAG
<b>DDIT 3</b>	TRCN0000368985	3	pLKO_TRC005	CCGGAGGTCTGTCTTC GATGAAACTCGAGTTCA TCTGAAGACAGGACCTTT TTTG	AATTCAAAAAGGTCT GTCTTCAGATGAAACCTC GAGTTTCATCTGAAGAC AGGACCT
<b>DDIT 3</b>	TRCN0000368983	4	pLKO_TRC005	CCGGAGAGCCCTCACTC TCCAGATTCTCGAGAATC TGGAGAGTGAGGGCTCT TTTTG	AATTCAAAAAGAGCCC TCACTCTCCAGATTCTC GAGAATCTGGAGAGTGA GGGCTCT
<b>MYO G</b>	TRCN0000430479	1	pLKO_TRC005	CCGGTGGCCACAGATGC CACTACTTCTCGAGAACT AGTGGCATCTGTGGCCAT TTTG	AATTCAAAAATGGCCAC AGATGCCACTACTTCTC GAGAAGTAGTGGCATCT GTGGCCA
<b>MYO G</b>	TRCN0000426530	2	pLKO_TRC005	CCGGCATTCTAGCTGCCTC CTTAGAGCTCGAGCTTA AGGAGGCAGCTGAATGTT TTTG	AATTCAAAAACATTCAAC TGCCTCCTTAGAGCTCG AGCTCTAAGGAGGCAG CTGAATG
<b>MZF1</b>	TRCN0000329828	1	pLKO_TRC005	CCGGACCAGAGCACCAA GCTCATTCTCGAGGAAT GAGCTTGGTGTCTGGTT TTTG	AATTCAAAAACACAGAG CACCAAGCTCATTCTC GAGGAATGAGCTTGGTG CTCTGGT
<b>MZF1</b>	TRCN0000329903	2	pLKO_TRC005	CCGGCCCGCAGGTCCAGG TAGTGTAACTCGAGTTAC ACTACCTGGACCTGCGGT TTTG	AATTCAAAAACCGCAGG TCCAGGTAGTGTAACTC GAGTTACACTACCTGGA CCTGCGG
<b>MZF1</b>	TRCN0000329830	3	pLKO_TRC005	CCGGTTTCCGGTGCTTC GCTATGACTCGAGTCATA GCGGAAGCACCGGAAATT TTTG	AATTCAAAAATTCCGGT GCTTCGCTATGACTCG AGTCATAGCGAAGCAC CGGAAA
<b>MZF1</b>	TRCN0000329905	4	pLKO_TRC005	CCGGACCGTGTGGACC AGATCTTCTCGAGAAAG ATCTGGTCCAGCACGGTT TTTG	AATTCAAAAACCGTGC TGGACCAGATTTCTC GAGAAAGATCTGGTCCA GCACGGT
<b>PATZ 1</b>	TRCN0000274379	1	pLKO_TRC005	CCGGTGTACTTGAACG GACATATCTCGAGATATGT	AATTCAAAAATGATCACT TGAACGGACATATCTCG

				CCGTTCAAGTGATCATTT TG	AGATATGTCCGTTCAAG TGATCA
<b>PATZ 1</b>	TRCN0000274414	2	pLKO_TRC005	CCGGACTATCAGCTCAA GGTATTCTCGAGAAATAC CTTGGAGCTGATAGTTTT TG	AATTCAAAAAACTATCAG CTCCAAGGTATTCCTCG AGAAATACCTGGAGCT GATAGT
<b>PATZ 1</b>	TRCN0000274416	3	pLKO_TRC005	CCGGCGAGTACTTGAGT CGGTGTTCTCGAGAACAC CGACTCAAAGTACTCGTT TTTG	AATTCAAAAACGAGTAC TTGAGTCGGTGTCTC GAGAACACCGACTCAA GTACTCG
<b>PATZ 1</b>	TRCN0000274417	4	pLKO_TRC005	CCGGAGATTGTTCAGTCG GCATTGCTGAGCAAAT GCCGACTGAACAATCTT TTTG	AATTCAAAAAGATTGTT CAGTCGGCATTGCTCG AGCAAATGCCACTGAA CAATCT
<b>POU2 F1</b>	TRCN0000232119	1	pLKO_TRC005	CCGGACAAACACAGAAC CGTGATTCTCGAGAAAT CACGGTTGCTGTGTTGTT TTTG	AATTCAAAAACAACAC AGCAACCGTGTTC GAGAAATCACGGTTGCT GTGTTGT
<b>POU2 F1</b>	TRCN0000232120	2	pLKO_TRC005	CCGGGCAACTGGGAACC TGGTATTCTCGAGAAATA CCAGGTTCCCAGTTGCTT TTTG	AATTCAAAAAGCAACTG GGAACCTGGTATTCTC GAGAAATACCAGGTTCC CAGTTGC
<b>POU2 F1</b>	TRCN0000232121	3	pLKO_TRC005	CCGGTTTCACTCTGCAGT GTGATTGCTCGAGCAATC ACACTGCAGAGTGAATT TTTG	AATTCAAAAATTCACTC TGCACTGTGATTGCTCG AGCAATCACACTGCAGA GTGAAA
<b>POU2 F1</b>	TRCN0000232118	4	pLKO_TRC005	CCGGGACCAAGCAGCTCA CCTATTAACTCGAGTTAA AGGTGAGCTGCTGGTCTT TTTG	AATTCAAAAAGACCAGC AGCTCACCTATTAACTC GAGTTAATAGGTGAGCT GCTGGTC
<b>USF1</b>	TRCN0000233475	1	pLKO_TRC005	CCGGCAGCTGCTGAGAC GCACTTAACTCGAGTATAG TGCCTCTCAGCAGCTTT TTTG	AATTCAAAAACAGCTGC TGAGACGCACTATACTC GAGTATAGTGCCTCA GCAGCTG
<b>USF1</b>	TRCN0000233477	2	pLKO_TRC005	CCGGGAGTAAGGTGGG ATTCTATCCTCGAGGATAG AATCCCACCTTACTCTTT TTG	AATTCAAAAAGAGTAA GGTGGGATTCTATCCTC GAGGATAGAATCCCACC TTTACTC
<b>USF1</b>	TRCN0000233476	3	pLKO_TRC005	CCGGCCCTAGGACTCAC CCTTATTCTCGAGGAATA AGGGTGAGTCTCTAGGGTT TTTG	AATTCAAAAACCCTAGG ACTCACCTTATTCTC GAGGAATAAGGGTGAGT CCTAGGG
<b>USF1</b>	TRCN0000233478	4	pLKO_TRC005	CCGGCACAGGTGGAAG ATCTTAAACTCGAGTTAA GATCTTCCACCTGTTGTTT TTG	AATTCAAAAACAACAGG TGGAAGATCTTAACTC GAGTTAAGATCTTCCA CCTGTTG
<b>XBP1</b>	TRCN0000277990	1	pLKO_TRC005	CCGGGAACAGCAAGTGG TAGATTACTCGAGTAAT CTACCACTGCTGTTCTT TTG	AATTCAAAAAGAACAGC AAGTGGTAGATTACTC GAGTAAATCTACCACTT GCTGTT
<b>XBP1</b>	TRCN0000278051	2	pLKO_TRC005	CCGGGCCTGCTGTACTT CATTCAACTCGAGTTGAA TGAAGTACAGACAGGGCTT TTTG	AATTCAAAAAGCCTGTC TGTACTTCATTCAACTCG AGTTGAATGAAGTACAG ACAGGC
<b>XBP1</b>	TRCN0000278050	3	pLKO_TRC005	CCGGGACCCAGTCATGTT CTTCAAACTCGAGTTGA AGAACATGACTGGCTTT TTTG	AATTCAAAAAGACCCAG TCATGTTCTCAAACCTC GAGTTGAAGAACATGA CTGGGTC
<b>XBP1</b>	TRCN0000277989	4	pLKO_TRC005	CCGGAGATCGAAAAGAAG GCTCGAATCTCGAGATTC GAGCCTTCTTCGATCTT TTTG	AATTCAAAAAGATCGA AAGAAGGCTCGAATCTC GAGATTGAGCCCTTCTT TCGATCT
<b>ZIC1</b>	TRCN0000421779	1	pLKO_TRC005	CCGGGGCCAGTTCTTGT CGAATTGCTCGAGCAATT CGACAAGAAACTGGCCTT TTTG	AATTCAAAAAGGCCAGT TTCTTGTCGAATTGCTC GAGCAATTGAGACAAGAA ACTGGCC
<b>ZIC1</b>	TRCN0000418658	2	pLKO_TRC005	CCGGCAATAGACCCAGGA CGAGTAACTCGAGTTACT CGTCCTGGTCTATTGTT TTTG	AATTCAAAAACAATAGAC CCAGGACGAGTAACTCG AGTTACTCGTCCTGGGT CTATTG

<b>ZIC1</b>	TRCN0000435544	3	pLKO_TRC005	CCGGGACTGATCACACAC GTATACTCGAGTGTATA CGTGTGTGATCAGTC TTG	AATTCAAAAAGACTGAT CACACACGTATACTC GAGTGTATAACGTGTG ATCAGTC
-------------	----------------	---	-------------	---	---